To investigate the association between genetic risk variants for age-related macular degeneration (AMD) and response to intravitreal ranibizumab in Korean patients with neovascular AMD.
This prospective study included 273 treatment-naive patients (273 eyes) who underwent 5 monthly injections (Months 0, 1, 2, 3, and 4) of intravitreal ranibizumab for neovascular AMD. Patients were genotyped for 23 single-nucleotide polymorphisms within 12 AMD-relevant genes. For each polymorphism, genotypic association with good response at Month 5, predetermined as visual improvement of ≥8 Early Treatment Diabetic Retinopathy Study letters from baseline, was investigated with logistic regression analysis adjusted for age, gender, smoking, baseline Early Treatment Diabetic Retinopathy Study letter, central retinal thickness, lesion area, and type of choroidal neovascularization.
At Month 5, visual acuity improved by 9.1 ± 17.6 letters from baseline, and 136 patients (49.8%) were classified as good responders. In logistic regression, no tested polymorphism showed statistically significant association with favorable visual outcome at Month 5. When unadjusted for multiple tests, AA genotype for VEGF rs699947 had an increased chance of good response compared with other genotypes (odds ratio, 3.61; 95% confidence interval, 1.42–9.18; P = 0.0071).
In this Korean neovascular AMD cohort, there was no statistically significant effect of genotype on early visual outcome after ranibizumab treatment.
A prospective cohort study including 273 treatment-naive Korean patients with neovascular age-related macular degeneration showed no statistically significant association between 23 age-related macular degeneration–relevant genetic risk variants and treatment outcome after 5 monthly injections of intravitreal ranibizumab.
*Department of Ophthalmology, College of Medicine, Seoul National University, Seoul, Korea;
†Department of Ophthalmology, National Medical Center, Seoul, Korea;
‡Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;
§DNA Link Inc, Seoul, Korea;
¶GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom; and
**Sensory Organs Institute, Medical Research Center, Seoul National University, Seoul, Korea.
Reprint requests: Hyeong Gon Yu, MD, PhD, Department of Ophthalmology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 110-799, Korea; e-mail: email@example.com
Supported by GlaxoSmithKline Medicines Research Centre, Stevenage, United Kingdom. The funding organization participated in part in the data management and analysis.
Paper presented at Association of Research in Vision and Ophthalmology Meeting, Fort Lauderdale, FL, May 2012.
None of the authors have any conflicting interests to disclose.